血浆置换联合血液滤过治疗慢性乙型重型肝炎的临床研究

目的 探讨血浆置换(PE)联合连续性静脉-静脉血液滤过(CVVH)治疗中，晚期慢性乙型重型肝炎的疗效及机制。方法 94例患者随机分3组，A组29例，B组31例，C组34例。A组内科治疗加PE联合CVVH治疗，B组内科治疗加PE治疗，C组仅予内科治疗。比较三组近期疗效及生存率，并观察A组和B组人工肝治疗前后血清细胞因子的改变。结果 A组肝性脑病意识转清率50．0％(5／10)，低钠血症改善，白细胞介素(IL)-8下降，IL-10上升，近期有效率82．8％，生存率48．3％；B组肝性脑病意识转清率I8．2％(2／11)，低钠血症、IL-8，IL-10无改变，近期有效率48．4％，生存率22．6％；C组肝性脑病意识转清率9．1％(1／11)，近期有效率26．5％，生存率20．6％。结论 内科治疗加PE联合CVVH能降低IL-8，升高IL-10，提高生存率，且方便可行，应作为非生物型人工肝支持的主要方法。

Clinical research of plasma exchange with continuous veno-venous hemofiltration in treating mid- and late-stage chronic severe viral hepatitis B patients

Objective To evaluate the clinical efficacy and study the mechanism of combining plasma exchange and continuous veno-venous hemofiltration in treating patients with chronic severe viral hepatitis B in their mid- and late stages. Methods 94 patients suffering from chronic severe viral hepatitis B were divided into three groups. 29 patients were treated with plasma exchange plus continuous veno-venous hemofiltration (group A). 31 patients were treated with plasma exchange alone (group B). 34 patients received routine treatment (group C). The efficacy of treatment and survival rate of the three groups was investigated. Before and after artificial liver support system treatment the levels of cytokine were examined. Results In group A, hyponatremia improved, the levels of interleukin 8 (IL-8) obviously decreased, the level of IL-10 increased, 5 of the 10 patients in coma regained normal consciousness (50.0%) and their survival rate was 48.3%. In group B, hyponatremia did not change, the level of IL-8 and IL-10 did not change. 2 of 11 patients in coma regained normal consciousness (18.2%) while survival rate was 22.6%. In group C, 1 of 11 patients in coma regained normal consciousness (9.1%) while survival rate was 20.6%. Conclusion It shows that plasma exchange with continuous veno-venous hemofiltration in treating patients with mid- and late stage chronic severe viral hepatitis B can increase the survival rate. IL-8 can be significantly removed, IL-10 significantly increased. This combined therapy is easy to practice, and should be used as an artificial liver support system.